ABBV · 10-Q · 2026Q2

AbbVie Inc.

Filed 2026-08-03 · Healthcare · View original filing on EDGAR

Everything ABBV's SEC filings said, ranked

Ranked Events

• Revenue Performance and MixImportance 59 · Surprise 48
  Worldwide net revenues increased 11.2% to $31.992 billion for the six months ended June 30, 2026, or 9.9% on a constant-currency basis. U.S. revenue increased 9.6% to $23.830 billion, while international revenue…
• Gross Margin DriversImportance 54 · Surprise 40
  Gross margin increased to $23.483 billion for the six months ended June 30, 2026 from $20.418 billion in the prior-year period. Gross margin as a percentage of net revenues increased for both the three and six months…
• Income Tax Rate ChangesImportance 40 · Surprise 56
  The effective tax rate declined to 19% for the six months ended June 30, 2026 from 31% in the prior-year period. The quarterly effective tax rate declined to 15% from 39% for the comparable three-month period. The…
• Regulatory EnvironmentImportance 34 · Surprise 60
  In January 2026, AbbVie entered a voluntary agreement with the U.S. government to lower Medicaid prices and expand affordable direct-to-patient offerings. AbbVie also pledged $100 billion of U.S.-based research and…
• Market Demand TrendsImportance 34 · Surprise 64
  Skyrizi and Rinvoq continued to gain market share across all indications, with six-month net revenues increasing 26% and 22%, respectively, on a constant-currency basis. Vraylar, Botox Therapeutic, Ubrelvy, Qulipta and…
• Acquisition / Partnership / DivestitureImportance 34 · Surprise 60
  AbbVie recorded $1.1 billion of payments for other acquisitions and investments, net of cash acquired, during the six months ended June 30, 2026. AbbVie recognized a $650 million upfront IPR&D charge for its license…
• Operating Expense TrendsImportance 34 · Surprise 58
  SG&A expense increased 10.1% to $7.210 billion for the six months ended June 30, 2026 from $6.546 billion. SG&A as a percentage of revenue was flat because revenue growth leverage offset higher litigation reserve…
• Balance Sheet and LiquidityImportance 33 · Surprise 24
  AbbVie maintained $8.0 billion of available unsecured revolving credit facilities at June 30, 2026, consisting of facilities maturing in March 2028 and January 2030. No amounts were outstanding under either revolving…
• Outstanding IndebtednessImportance 33 · Surprise 42
  AbbVie issued $8.0 billion of unsecured senior notes during the six months ended June 30, 2026. The company repaid $2.0 billion of its 364-day term loan credit agreement and $2.0 billion of 3.20% senior notes during…
• Cash Flow and Capital AllocationImportance 33 · Surprise 32
  Operating cash flow increased to $7.265 billion for the six months ended June 30, 2026 from $6.788 billion, primarily due to stronger operating results and lower litigation payments. Capital expenditures increased to…
• Guidance / OutlookImportance 31 · Surprise 42
  AbbVie’s 2026 strategy emphasizes its diversified revenue base, international commercial infrastructure and continued investment in new product launches and established brands. Management plans to expand its pipeline…
• Manufacturing CapacityImportance 9 · Surprise 42
  AbbVie announced a pharmaceutical manufacturing campus in North Carolina incorporating advanced manufacturing, laboratory technologies and artificial intelligence. The campus is intended to support production of…
• U.S. Manufacturing InvestmentImportance 9 · Surprise 42
  AbbVie announced a pharmaceutical manufacturing campus in North Carolina incorporating advanced manufacturing, laboratory technologies, and artificial intelligence. The company also announced two new manufacturing…
• Regulatory Approval MilestonesImportance 7 · Surprise 60
  AbbVie obtained U.S. and European approvals expanding Skyrizi into pediatric plaque psoriasis and Venclexta/Venclyxto into previously untreated chronic lymphocytic leukemia combinations. Decnupaz was approved in the…
• Distribution ChannelsImportance 6 · Surprise 6
  AbbVie sells products worldwide through AbbVie-owned distribution centers and public warehouses to wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies and independent retailers.…
• Product Pipeline ProgressImportance 5 · Surprise 30
  AbbVie’s development pipeline includes approximately 90 compounds, devices or indications, including approximately 60 programs in mid- and late-stage development. The pipeline is focused on immunology, neuroscience,…

Revenue by Product (in millions)

Revenue by Geography (in millions)